Anthem Blue Cross Helps Health Centers in Underserved Regions of California Offer Specialty Healthcare Services to Uninsured Patients

Funding connects Central Valley and north rural county primary care centers with specialists to treat patient needs onsite, without requiring visits to other clinics and providers. FRESNO, Calif.–(BUSINESS WIRE)–$Anthem #Alpine–Anthem Blue Cross, a leading coordinator of managed healthcare services in California, has made a new commitment that will continue to give uninsured Californians access to … [Read more…]

Veranex Joins Industry Leaders as a Sponsor for the Stanford Byers Center for Biodesign

Veranex is the first medtech innovation solutions firm to sponsor Stanford Biodesign RALEIGH, N.C.–(BUSINESS WIRE)–#biodesign—Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medtech industry, today announced that it has joined industry leaders as corporate sponsors for the Stanford Byers Center for Biodesign. Stanford Biodesign trains and supports students, fellows, faculty, and … [Read more…]

InvisiShield Technologies Collaborates with Gladstone Institutes to Accelerate Development of Intranasal Preventatives against SARS-CoV-2, Influenza, and RSV

EMERYVILLE, Calif.–(BUSINESS WIRE)–InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, today announced a collaboration with Gladstone Institutes to develop intranasal preventatives against airborne infection, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV). Gladstone Institutes, a non-profit biomedical research organization that uses visionary science and technology to … [Read more…]

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, March 27, 2023, at 8:00 a.m. ET to review its fourth quarter and full year 2022 financial results and provide an update … [Read more…]

OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

— Trial will evaluate the insulin-sensitizing effects of TLC-3595, alone and in combination with approved diabetes therapies — PALO ALTO, Calif.–(BUSINESS WIRE)–#diabetes–OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA … [Read more…]

Synchron to Begin Patient Enrollment for the COMMAND Trial of Brain-Computer Interface at Gates Vascular Institute

Milestone marks new opportunity for patients with severe paralysis to receive groundbreaking Synchron Switch™ brain-computer interface NEW YORK–(BUSINESS WIRE)–#BCI—Synchron, the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching … [Read more…]

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #LineageCellTherapeutics—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting … [Read more…]

Icosagen Acquires the Carterra LSA Instrument to Significantly Enhance Its Antibody Screening Capabilities in the Discovery and Development of New Therapeutic and Diagnostic Antibodies

The addition of the LSA increases Icosagen’s end-to-end service capabilities for drug companies developing therapeutics worldwide TARTU, Estonia & SALT LAKE CITY, Utah–(BUSINESS WIRE)–Icosagen Group, an established research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, today announced that it has acquired the LSA® platform from Carterra®, a leading provider of … [Read more…]

TeleHealth Solution Is Now Fident Health, As Company Rapidly Expands Virtual Hospitalist Services to Rural and Suburban America

ADDISON, Texas–(BUSINESS WIRE)–Fident Health is the new name of TeleHealth Solution, a leading provider of virtual hospitalist telehealth services to rural and suburban hospitals and post-acute care centers. Fident Health brings a scalable solution to rural hospitals that delivers timely, accessible and state-of-the-art care to their communities. “Many hospitals outside of major metropolitan hubs are … [Read more…]

Exelixis Announces $550 Million Share Repurchase Program

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including … [Read more…]